|
CFCF is pleased to announce that this E-Update is supported by Novartis Pharmaceuticals Corporation |
Follow us on Twitter!
 Join us on Facebook!
Visit us on Navigating Cancer! |
Survivor Stories

Submitted 5/2010
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients.
|
|
Join Us for a Cure
Make a difference and get involved with CFCF! Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events! |
Give hope and a future to neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible. We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible.
To learn more, view CFCF's: Audited Financial Statements IRS From 990
|
|
We are proud to be a BBB accredited charity!
CFCF meets all 20 Wise Giving Alliance standards for charity accountability established by the Better Business Bureau. Click here to check out the CFCF Wise Giving Report. | |
|
|
|
|
|
Washington Post features carcinoid patient's difficult road to diagnosis
 After years of presenting symptoms, it was not until August 2005 that Jan Weymouth was diagnosed with advanced carcinoid cancer in her lungs. A veteran employee of the National Institutes of Health, Weymouth was dismissed by doctors as a hypochondriac as she repeatedly complained about a sharp pain on the left side of her rib cage. Weymouth consulted an orthopedist and a rheumatologist about the pain she was feeling and both suggested that she undergo physical therapy for what they believed to be a torn muscle. When physical therapy made the pain worse, Weymouth turned to over-the-count pain relievers.
Over the course of a year, Weymouth gained over 60 pounds, which she thought was due to stress-related eating, and decided to undergo weight-loss surgery. Scans conducted during her pre-op physical revealed lesions on Weymouth's lung and ribs; she was instructed to see an oncologist immediately. Three weeks later, Weymouth was diagnosed with carcinoid cancer.
Having undergone surgery, chemotherapy, radiation, and experimental protocols, Weymouth has been able to control her disease relatively well. Her story highlights the difficulties undiagnosed carcinoid cancer and related neuroendocrine tumor patients face when trying to identify the source of their symptoms. Click here to read the full story.
We encourage you to share your story with fellow patients and caregivers. Click here to post your Survivor Story to the Caring for Carcinoid Foundation website. |
|
CFCF awards grant to UK Mouse Model Project Internationally established researcher, David Tuveson, M.D., Ph.D., will use his laboratory's expertise in forward genetics and mouse cancer modeling to both generate models of neuroendocrine tumors and simultaneously identify genes and pathways that promote neuroendocrine tumor formation. This study will uncover the critical genetic alterations and pathways that regulate the development of neuroendocrine tumors. Once identified, these genetic events will be used to generate mouse models of neuroendocrine tumors. These genetic events may also represent novel therapeutic targets in neuroendocrine tumors. This ambitious study will be conducted in Dr. Tuveson's lab at the Cancer Research UK Cambridge Research Institute. To read more about this ground-breaking study, visit the CFCF website. To learn more about Dr. Tuveson's previous research and for a list of his publications, click here. |
|
Novartis drug promising for advanced pancreatic neuroendocrine tumor patients
 On June 3, 2010 Novartis announced that RADIANT-3, a Phase III study of Afinitor tablets plus best supportive care, met its primary endpoint showing that the drug significantly extended progression-free survival in patients with advanced pancreatic neuroendocrine tumors. Afinitor (everolimus) is currently approved for treatment of patients with advanced renal cell carcinoma whose disease has progressed on or after VEGF-targeted therapy.
Surgery and chemotherapy are currently the only approved treatment options for patients with advanced pancreatic neuroendocrine tumors. Results from RADIANT-3 suggest that Afinitor has the potential to become an important treatment option for these patients. Full results of this study will be presented later in 2010. Click here to read the press release issued by Novartis. |
|
CFCF Founder Nancy Lindholm named MGH "one hundred" honoree
 Massachusetts General Hospital (MGH) is honoring CFCF Founder and Director Nancy Lindholm at its annual "one hundred" gala. This fundraising event celebrates one hundred individuals and groups whose diligence and discoveries, philanthropy and passion have helped advance the fight against cancer. Funds raised at the event will support patient care, research, education and community outreach programs at the MGH Cancer Center. For more information on the one hundred, and for a list of honorees, click here. |
|
Featured Event: 2010 Country Music Marathon!
 We would like to express our gratitude for the 21 individuals that participated on behalf of CFCF in this year's Country Music Marathon in Nashville, Tennessee! This year, these Team CFCF marathoners raised over $15,000!
Since 2008, Team CFCF has been led by team captain, Sarah Farnell, in the Country Music Marathon. Sarah runs in memory of her sister, Payton Farnell Graeber, who passed away in 2007 from carcinoid cancer at the young age of 29. Explaining why she runs, Sarah writes "Before Payton's death, I had never been a runner and didn't like it... Every day is still so sad - but raising money for CFCF gives us a chance to do something good and positive for other families who are dealing with carcinoid cancer and related neuroendocrine tumors."
We thank Sarah Farnell, the 2010 CMM marathoners, and every Team CFCF athlete that helps us raise awareness and funds for a cure! |
|
Upcoming CFCF Events
 The season for running, cycling, and swimming events is upon us! Join Team CFCF in any number events nationwide to run, bike, or swim to a cure.
Team CFCF participants raise awareness for carcinoid cancer and related neuroendocrine tumors and raise much needed funds for scientific research. 100% of every dollar raised at our fundraising events goes to cutting-edge carcinoid cancer and neuroendocrine tumor research. |
|
Advertisement from our Sponsor | |
|
|
|